Table 1.

Three clinical groups of study patients

Group 1: Hepatocellular damage (n = 229)	Group 2: Obstructive/cholestatic (n = 56)	Group 3: Miscellaneous (n = 38)
Chronic hepatitis C (n = 117)	Primary biliary cirrhosis (n = 24)	Cryptogenic (n = 29)
Alcoholic (n = 49)	Primary sclerosing cholangitis (n = 29)	Alpha-1-antitrypsin deficiency (n = 6)
Chronic hepatitis C plus alcoholic (n = 28)	Biliary atresia (n = 2)	Alagille’s syndrome(n = 1)
Chronic hepatitis B (n = 8)	Sarcoidosis (n = 1)	Polycystic liver disease (n = 1)
Autoimmune hepatitis (n = 12)	Cystic fibrosis (n = 2)	Hereditary hemorrhagic telangiectasia (n = 1)
Hemochromatosis (n = 3)
Wilson’s disease (n = 2)
Non-alcoholic steatohepatitis (n = 10)